Posters
Presenting Author Academic/Professional Position
Mohammed Sikander
Academic Level (Author 1)
Faculty
Discipline/Specialty (Author 1)
Cancer and Immunology
Academic Level (Author 2)
Post-doc
Discipline/Specialty (Author 2)
Cancer and Immunology
Academic Level (Author 3)
Medical Student
Discipline/Specialty (Author 3)
Cancer and Immunology
Discipline Track
Biomedical Science
Abstract Type
Research/Clinical
Abstract
Cervical cancer (CxC) is a leading cause of mortality and morbidity among women worldwide. Current chemotherapeutic agents for CxC have shown systemic toxicity in CxC patients. Ormeloxifene (ORM) is a non-toxic and non-steroidal drug with well-defined pharmacokinetic and pharmacodynamic properties in humans. In this study, we introduce a new analogue of ormeloxifene, Bromo-ormeloxifene (Br-ORM), which demonstrates enhanced therapeutic efficacy against CxC in both in vitro and in vivo models. We investigated Br-ORM's effects on CxC cell growth through colony formation and MTS assays, alongside molecular docking studies with βcatenin using AutoDock4. Furthermore, we analyzed the influence of Br-ORM on the expression of epithelial-to-mesenchymal (EMT) markers and MMPs via Western blot and qPCR, and assessed apoptosis through Annexin-V staining. Immunofluorescence analysis highlighted the drug’s impact on β-catenin localization within cells, while the anti-tumor efficacy was evaluated in an orthotopic xenograft mouse model. Results indicated that Br-ORM notably inhibited CxC cell proliferation, decreased invasion and migration, and promoted apoptosis, along with reducing EMT-related markers and β-catenin translocation. Additionally, bioinformatics revealed a strong binding affinity of Br-ORM to β-catenin. These findings collectively suggest that Br-ORM effectively targets the β-catenin signaling pathway, thereby inhibiting CxC metastasis, indicating its potential utility as a new therapeutic alternative for treating cervical cancer.
Presentation Type
Poster
Recommended Citation
Sikander, Mohammed; Malik, Shabnam; Kumari, Sonam; Apraku, John; Biju, Theresa M.; Halaweish, Fathi T.; Yallapu, Murali; Jaggi, Meena; and Chauhan, Subhash, "Disruption of β-Catenin Signaling as a Strategy to Suppress EMT in Cervical Cancer" (2025). Research Colloquium. 42.
https://scholarworks.utrgv.edu/colloquium/2025/posters/42
Included in
Disruption of β-Catenin Signaling as a Strategy to Suppress EMT in Cervical Cancer
Cervical cancer (CxC) is a leading cause of mortality and morbidity among women worldwide. Current chemotherapeutic agents for CxC have shown systemic toxicity in CxC patients. Ormeloxifene (ORM) is a non-toxic and non-steroidal drug with well-defined pharmacokinetic and pharmacodynamic properties in humans. In this study, we introduce a new analogue of ormeloxifene, Bromo-ormeloxifene (Br-ORM), which demonstrates enhanced therapeutic efficacy against CxC in both in vitro and in vivo models. We investigated Br-ORM's effects on CxC cell growth through colony formation and MTS assays, alongside molecular docking studies with βcatenin using AutoDock4. Furthermore, we analyzed the influence of Br-ORM on the expression of epithelial-to-mesenchymal (EMT) markers and MMPs via Western blot and qPCR, and assessed apoptosis through Annexin-V staining. Immunofluorescence analysis highlighted the drug’s impact on β-catenin localization within cells, while the anti-tumor efficacy was evaluated in an orthotopic xenograft mouse model. Results indicated that Br-ORM notably inhibited CxC cell proliferation, decreased invasion and migration, and promoted apoptosis, along with reducing EMT-related markers and β-catenin translocation. Additionally, bioinformatics revealed a strong binding affinity of Br-ORM to β-catenin. These findings collectively suggest that Br-ORM effectively targets the β-catenin signaling pathway, thereby inhibiting CxC metastasis, indicating its potential utility as a new therapeutic alternative for treating cervical cancer.
